Source: European Medicines Agency (EU) Revision Year: 2023 Publisher: Astellas Pharma Europe B.V., Sylviusweg 62, 2333 BE Leiden, The Netherlands
Veoza 45 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). Round, light red tablets (approximately 7 mm diameter × 3 mm thickness), debossed with the company logo and ‘645’ on the same side. |
Each film-coated tablet contains 45 mg of fezolinetant.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Fezolinetant |
Fezolinetant is a non-hormonal selective neurokinin 3 (NK3) receptor antagonist. It blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron, which is postulated to restore the balance in KNDy neuronal activity in the thermoregulatory centre of the hypothalamus. |
| List of Excipients |
|---|
|
Core tablet: Mannitol (E421) Film coating: Hypromellose (E464) |
PA/Aluminium/PVC/Aluminium unit dose blisters in cartons.
Pack sizes: 28 × 1, 30 × 1, and 100 × 1 film-coated tablets.
Not all pack sizes may be marketed.
Astellas Pharma Europe B.V., Sylviusweg 62, 2333 BE Leiden, The Netherlands
EU/1/23/1771/001
EU/1/23/1771/002
EU/1/23/1771/003
| Drug | Countries | |
|---|---|---|
| VEOZA | Estonia, France, Croatia, Ireland, Lithuania, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
